Skip to main content
SpringerLink
Log in

Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-α2

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The antiproliferative action of the antiestrogen toremifene and recombinant human interferon-α2a (IFN-α2a) were examined on human breast cancer cell lines grown in culture and in the athymic mouse.

Solid tumors grew from an inoculation of a 99:1 ratio of hormone dependent (MCF-7) and hormone independent (MDA-MB-231) breast cancer cells without estrogen administration. However, estradiol supplementation significantly increased the rate of tumor growth. The daily administration of 1.35 × 106 U of recombinant human IFN-α2a resulted in a marked reduction of tumor growth in both estradiol-treated and non-treated mice. Toremifene administration (130 µg/day from a sustained release preparation) markedly inhibited estradiol stimulation of mouse uterine weight and partially reduced estradiol-stimulated tumor growth. The combination of IFN-α2a (1.35 × 106 u/day) with toremifene (130 µg/day) reduced estradiol-stimulated growth much below that of toremifene alone but not below that seen with interferon alone.

Toremifene (10−10-10−6M) did not inhibit the growth of hormone-independent MDA-MB-231 breast cancer cellsin vitro whereas it did inhibit the growth of hormone-dependent MCF-7 cells in phenol red containing media. IFN-α2a (1–10,000 u) inhibited the growth of both MCF-7 and MDA-MB-231 cells in culture; however, MCF-7 cells were approximately 10-fold more sensitive to interferon inhibition. This was consistent with the MCF-7 cells showing a greater sensitivity to interferon than MDA-MB-231 cells in the induction of 2′5′-oligoadenylate synthetase.

The heterogeneous tumor model in the athymic mouse suggests that differential sensitivities of breast cancer cells to the antiproliferative actions of interferon may influence the effectiveness of combination therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Furr BJA, Jordan VC: Pharmacology and clinical use of tamoxifen. Pharmacol Ther 25: 127–203, 1984

    PubMed  Google Scholar 

  2. King WJ, DeSombre ER, Jensen EV, Greene GL: Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 45: 293–304, 1985

    PubMed  Google Scholar 

  3. Shimada A, Kimura S, Abe K, Nagasaki K, Adachi I, Yamaguchi K, Suzuki M, Nakajima T, Miller LS: Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections. Proc Natl Acad Sci USA 82: 4803–4807, 1985

    PubMed  Google Scholar 

  4. Perrot-Applanat M, Groyer-Picard M-T, Lorenzo F, Jolivet A, Hai MTV, Pallud C, Spyratos F, Milgrom E: Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors. Cancer Res 47: 2652–2661, 1987

    PubMed  Google Scholar 

  5. Van Netten JP, Algard FT, Coy P, Carlyle SJ, Brigden ML, Thornton KR, Peter S, Fraser T, To MP: Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast cancers. Cancer 56: 2019–2024, 1985

    PubMed  Google Scholar 

  6. Robinson SP, Jordan VC: Antiestrogenic actions of toremifene in hormone-dependent, independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 48: 1758–1762, 1989

    Google Scholar 

  7. Taylor-Papadimitriou J, Shearer M, Balkwill FR, Fantes KH: Effects of HuIFN-α2 and HuIFN-α (Namalwa) on breast cancer cell growth in culture and as xenografts in the nude mouse. J Interferon Res 2: 479–491, 1982

    PubMed  Google Scholar 

  8. Balkwill FR, Goldstein L, Stebbing N: Differential action of six human interferons against two human carcinomas growing in nude mice. Int J Cancer 35: 613–617, 1985

    PubMed  Google Scholar 

  9. van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J: Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the antiproliferative effect of tamoxifen. Br J Cancer 55: 255–257, 1987

    PubMed  Google Scholar 

  10. Gutterman JV, Blumenschien AR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93: 399–406, 1980

    PubMed  Google Scholar 

  11. Borden EC, Holland JF, Dao TL, Gutterman JU, Wiener L, Chang YC, Patel J: Leukocyte-derived interferon (α) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med 97: 1–6, 1982

    PubMed  Google Scholar 

  12. Goldstein D, Lazlo J: Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46: 4315–4329, 1986

    PubMed  Google Scholar 

  13. Berthois J, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500, 1986

    PubMed  Google Scholar 

  14. LaBarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Analyt Biochem 102: 344–352, 1980

    PubMed  Google Scholar 

  15. Merritt JA, Borden EC, Ball LA: Measurement of 2′5′-oligoadenylate synthetase in patients receiving interferonalpha. J Interferon Res 5: 191–198, 1985

    PubMed  Google Scholar 

  16. Grossberg SE, Taylor JL, Sieberlist RE, Jameson P: Biological and immunological assays of human interferons. In: Rocklin R (ed) Manual of Clinical Immunology, 3rd ed. ASM Publishing, Washington DC, 1986, pp 295–299

    Google Scholar 

  17. Kimoto Y, Fujita M, Tagucha T: Interferon treatment of human stomach and breast carcinoma xenografts in nude mice. J Interferon Res 7: 345–356, 1987

    PubMed  Google Scholar 

  18. Gutterman JN, Fine S, Quesada J, Horning S, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z: Recombinant leukocyte A interferon: Pharmacokinetics, single dose tolerance and biologic effects in cancer patients. Ann Int Med 96: 549–556, 1982

    PubMed  Google Scholar 

  19. Kangas L, Nieminen A-C, Cantell K: Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a) and human interferons on estrogen responsive MCF-7 cellsin vitro. Medical Biology 63: 187–190, 1985

    PubMed  Google Scholar 

  20. Goldstein D, Bushymeyer M, Witt PL, Jordan VC, Borden EC: Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res 49: 2698–2702, 1989

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Simon P. Robinson

    Present address: Experimental Therapeutics Department, Bristol Myers Company, 5 Research Parkway, P.O. Box 5100, 06492, Wallingford, CT, USA

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 600 Highland Avenue, 53792, Madison, WI, USA

    Simon P. Robinson, David Goldstein, Patricia L. Witt, Ernest C. Borden & V. Craig Jordan

Authors
  1. Simon P. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia L. Witt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ernest C. Borden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, S.P., Goldstein, D., Witt, P.L. et al. Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-α2. Breast Cancer Res Tr 15, 95–101 (1990). https://doi.org/10.1007/BF01810781

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01810781

Key words

Search

Navigation